A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
The main purpose of this study is learn about the the safety and side effects of the study drug, RGX-104. RGX-104 is an experimental drug. This means that RGX-104 is not approved by the Food and Drug Administration (FDA). This is the first time RGX-104 will be given to humans.
Are you Eligible? (Inclusion Criteria)
- Do you have a confirmed solid tumor?
- Have you had treatment for your disease before? Or is there not a standard treatment available for your disease?
- Does your cancer continue to grow? Can your cancer not be removed by surgery?
- Are you 18 years of age or older?